Product nameAnti-Cyclin D1 antibody [EP272Y]
See all Cyclin D1 primary antibodies
DescriptionRabbit monoclonal [EP272Y] to Cyclin D1
Tested applicationsSuitable for: WB, IHC-P, ICC/IF, IPmore details
Unsuitable for: Flow Cyt
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide corresponding to residues near the N-terminus (Human)
- WB: HeLa membrane extract lysate (ab29547), MCF-7 cell lysate. ICC/IF: MCF7 cells. IHC-P: Human kidney carcinoma and human hepatocellular carcinoma tissues.
A trial size is available to purchase for this antibody.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents
This product is a recombinant rabbit monoclonal antibody.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferpH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab40754 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Detects a band of approximately 35 kDa (predicted molecular weight: 33 kDa).|
|IHC-P||1/250 - 1/500.|
|ICC/IF||1/50 - 1/100.|
|IP||1/10 - 1/100.|
FunctionEssential for the control of the cell cycle at the G1/S (start) transition.
Involvement in diseaseNote=A chromosomal aberration involving CCND1 may be a cause of B-lymphocytic malignancy, particularly mantle-cell lymphoma (MCL). Translocation t(11;14)(q13;q32) with immunoglobulin gene regions. Activation of CCND1 may be oncogenic by directly altering progression through the cell cycle.
Note=A chromosomal aberration involving CCND1 may be a cause of parathyroid adenomas. Translocation t(11;11)(q13;p15) with the parathyroid hormone (PTH) enhancer.
Defects in CCND1 are a cause of multiple myeloma (MM) [MIM:254500]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving CCND1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus.
Sequence similaritiesBelongs to the cyclin family. Cyclin D subfamily.
modificationsPhosphorylation at Thr-286 by MAP kinases is required for ubiquitination and degradation following DNA damage. It probably plays an essential role for recognition by the FBXO31 component of SCF (SKP1-cullin-F-box) protein ligase complex.
Ubiquitinated, primarily as 'Lys-48'-linked polyubiquitination. Ubiquitinated by a SCF (SKP1-CUL1-F-box protein) ubiquitin-protein ligase complex containing FBXO4 and CRYAB (By similarity). Following DNA damage it is ubiquitinated by some SCF (SKP1-cullin-F-box) protein ligase complex containing FBXO31. Ubiquitination leads to its degradation and G1 arrest. Deubiquitinated by USP2; leading to stabilize it.
- Information by UniProt
- AI327039 antibody
- B cell CLL/lymphoma 1 antibody
- B cell leukemia 1 antibody
Lane 1: Empty
Lane 2: Wild-type HAP1 whole cell lysate (20 µg)
Lane 3: Cyclin D1 knockout HAP1 whole cell lysate (20 µg)
Lane 4: A431 whole cell lysate (20 µg)
Lanes 1 - 4: Merged signal (red and green). Green - ab40754 observed at 35 kDa. Red - loading control, ab18058, observed at 130 kDa.
ab40754 was shown to specifically recognize Cyclin D1 when HAP1 in wild-type HAP1 cells along with additional cross reactive bands. No band was observed when knockout samples were examined. Wild-type and HAP1 knockout samples were subjected to SDS-PAGE. ab40754 and ab18058 (Mouse anti Vinculin loading control) were incubated overnight at 4°C at 1/1000 dilution and 1/10,000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1/10,000 dilution for 1 hour at room temperature before imaging.
ab40754 staining cyclin D1 in MCF7 cells treated with KN-93 (water soluble) (ab120980), by ICC/IF. Decrease in cyclin D1 expression correlates with increased concentration of KN-93 (water soluble), as described in literature.
The cells were incubated at 37°C for 24 hours in media containing different concentrations of ab120980 (KN-93 (water soluble)) in DMSO, fixed with 100% methanol for 5 minutes at -20°C and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab40754 (1/100 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A goat anti-rabbit DyLight 488 goat anti-rabbit secondary antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
Anti-Cyclin D1 antibody [EP272Y] (ab40754) at 1/2000 dilution + MCF-7 cell lysate at 10 µg
Predicted band size: 33 kDa
Observed band size: 36 kDa why is the actual band size different from the predicted?
Immunohistochemical analysis of paraffin-embedded human kidney carcinoma using anti-Cyclin D1 RabMAb (ab40754).
Immunohistochemical analysis of paraffin-embedded human hepatocellular carcinoma using anti-Cyclin D1 RabMAb (ab40754).
This product has been referenced in:
- Zhang C et al. HEF1 regulates differentiation through the Wnt5a/ß-catenin signaling pathway in human gastric cancer. Biochem Biophys Res Commun 509:201-208 (2019). Read more (PubMed: 30579603) »
- Li N et al. Effects of isoliquiritigenin on ovarian cancer cells. Onco Targets Ther 11:1633-1642 (2018). Read more (PubMed: 29606882) »